BACKGROUND: Topical, intraocular, oral, and parenteral steroids might increase intraocular pressure (IOP), but little is known regarding the effect of nasal steroid spray. OBJECTIVE: We sought to examine the effect of discontinuing nasal steroid sprays on IOP in patients with glaucoma. METHODS: A retrospective chart review of patients with glaucoma using nasal steroids was performed. Averaged IOP for each pair of eyes was determined for presteroid use, steroid use, and 2 consecutive poststeroid use (poststeroid 1 and poststeroid 2) examinations. RESULTS: Twenty-four eyes of 12 patients taking nasal steroids were identified. The mean IOP for each pair of eyes was 15.4 +/- 4.3 mm Hg (range, 9-23.5 mm Hg) for the presteroid use examination, 18.0 +/- 3.8 mm Hg (range, 12-24.5 mm Hg) for the steroid use examination, 14.5 +/- 3.3 mm Hg (range, 9.5-20 mm Hg) for poststeroid use examination 1, and 14.8 +/- 3.4 mm Hg (range, 95-22.0 mm Hg) for poststeroid use examination 2. Eleven patients experienced decreased averaged IOP at poststeroid use examination 1 after steroid discontinuation at a mean of 35 +/- 14 days and continued to maintain this decrease on the poststeroid use examination 2 visit at a mean of 191 +/- 150 days. A significant increase between presteroid and steroid use examination IOPs (P = .007) and a significant decrease between steroid use and both poststeroid use 1 (P < .001) and poststeroid use 2 (P = .011) examination IOPs were observed. No significant difference between presteroid use and either poststeroid use examination IOPs (P = 1.00) was found. Many patients met their target pressures and were able to avoid or delay additional glaucoma therapy. CONCLUSION: A significant reduction in IOP occurred with nasal steroid discontinuation in patients with glaucoma. Nasal steroids might contribute to IOP increase, and inquiry as to whether a patient has glaucoma before medication initiation is warranted.
BACKGROUND: Topical, intraocular, oral, and parenteral steroids might increase intraocular pressure (IOP), but little is known regarding the effect of nasal steroid spray. OBJECTIVE: We sought to examine the effect of discontinuing nasal steroid sprays on IOP in patients with glaucoma. METHODS: A retrospective chart review of patients with glaucoma using nasal steroids was performed. Averaged IOP for each pair of eyes was determined for presteroid use, steroid use, and 2 consecutive poststeroid use (poststeroid 1 and poststeroid 2) examinations. RESULTS: Twenty-four eyes of 12 patients taking nasal steroids were identified. The mean IOP for each pair of eyes was 15.4 +/- 4.3 mm Hg (range, 9-23.5 mm Hg) for the presteroid use examination, 18.0 +/- 3.8 mm Hg (range, 12-24.5 mm Hg) for the steroid use examination, 14.5 +/- 3.3 mm Hg (range, 9.5-20 mm Hg) for poststeroid use examination 1, and 14.8 +/- 3.4 mm Hg (range, 95-22.0 mm Hg) for poststeroid use examination 2. Eleven patients experienced decreased averaged IOP at poststeroid use examination 1 after steroid discontinuation at a mean of 35 +/- 14 days and continued to maintain this decrease on the poststeroid use examination 2 visit at a mean of 191 +/- 150 days. A significant increase between presteroid and steroid use examination IOPs (P = .007) and a significant decrease between steroid use and both poststeroid use 1 (P < .001) and poststeroid use 2 (P = .011) examination IOPs were observed. No significant difference between presteroid use and either poststeroid use examination IOPs (P = 1.00) was found. Many patients met their target pressures and were able to avoid or delay additional glaucoma therapy. CONCLUSION: A significant reduction in IOP occurred with nasal steroid discontinuation in patients with glaucoma. Nasal steroids might contribute to IOP increase, and inquiry as to whether a patient has glaucoma before medication initiation is warranted.
Authors: Anastasiya Vinokurtseva; Matthew Fung; Erica Ai Li; Richard Zhang; James J Armstrong; Cindy M L Hutnik Journal: Clin Ophthalmol Date: 2022-05-30